Orexo acquires US rights to commercialise vorvida

Swedish company Orexo has purchased the exclusive US rights to vorvida, a digital therapy to treat alcohol use disorder (AUD), from GAIA, for an undisclosed sum. In August, Orexo signed an agreement with GAIA to secure exclusive secure global commercial rights to OXD01, a digital therapy being developed to treat OUD. Under the deal, Orexo will take responsibility for the regulatory approval and commercialisation of vorvida digital therapy in the US. The deal allows GAIA to secure an upfront payment, milestone payments and royalties. Both firms will also negotiate with the FDA regarding the regulatory pathway of digital therapy to help determine the timing of the therapy’s launch in the US and the need for additional investments. GAIA CEO and founder Dr Mario Weiss said: “Working with the Orexo team on the first agreement showed us their dedication and vision of the potential for digital therapeutics in the field of addiction.”